International

Asia Pacific

Trinity has been working in the APAC region for over 10 years and has completed over 150 projects related to the region. There are ~20 Trinity experts associated with the Asia Pacific Center of Excellence.

Home / International / Asia Pacific

Trinity supports global and local clients with commercialization strategies in the APAC region, in addition to supporting local clients with global expansion strategies

We leverage our expertise of APAC markets to develop recommendations and strategies pertinent to local needs
We bring APAC-specific and evidence-based insights to support our recommendations
We enhance communication and collaboration across global and APAC teams to ensure local needs are addressed

Supporting All Commercialization Needs
- Corporate & New Product Strategy
  - Corporate Strategy
  - Business Development
  - New Product Planning
- Launch & Brand Excellence
  - Launch Planning
  - Brand Planning
  - Strategic Competitive Intelligence
- Evidence, Value, Access & Pricing
  - Evidence Strategy
  - Value, Access & Pricing
- Primary & Secondary Insights
  - Qualitative and Quantitative Research
Typical Business Questions
What is our China go-to-market strategy?
- Should we target Tier 1 vs other Tier cities? How should we approach reaching the rural segment?
- How should we consider partnerships / joint ventures with local companies?
- What accelerated commercialization options can I leverage (e.g., Free Trade Zones, breakthrough therapy)?
How should we be organized across different APAC markets?
- What business model would ensure optimal collaboration between global/HQ teams and local affiliates?
- What business model would I need for APAC? Are there ‘archetypes’ across regions?
- How should we invest/partner with local/regional R&D hubs (e.g., China, Singapore)?
- What commercial capabilities do we need to build to remain competitive in the future?
How do we ensure pricing and market access success?
- Is national reimbursement in China still the ‘best option’? How sustainable is a private insurance / cash-pay model?
- What price can we expect in local markets? How should we consider local/regional price referencing?
- What innovative access and reimbursement options could we explore (e.g., hospital reimbursement pathway, Nanbayu, pay-by-installments)
How do I maximize value in local markets?
- What are opportunities to optimize our portfolio to meet local needs (e.g., medical, economic)?
- How should we accelerate global development programs to meet specific needs in APAC?
- What local innovation and business development opportunities should we pursue?
Unique regional capabilities
- Multilingual experts that are fluent in local language (Chinese, Japanese, Korean, etc.) to ensure optimal execution of research programs
- Extensive network of stakeholder types, including KOLs, providers, regulatory experts, payers and patients
- Ability to conduct market research in different formats (in-person, telephone, video platform, central facility, web survey)

Latest Asia Pacific Intelligence

Blog

Japan’s Latest Drug Pricing Policy Updates: Off-Year Revision and Other Anticipated Changes in 2023

February 27, 2023 Executive Summary: Introduction & History of the Regular Price Revisions in Japan For over two decades, Japan has maintained a biennial re-pricing approach in which drug prices are surveyed through wholesaler offices and healthcare institutions to capture the product discrepancy rates between National Health Insurance (NHI) prices and actual sales prices (i.e., […]

White Papers

Cracking the Code of the Access Landscape in China

As the market becomes increasingly crowded and budget constraints continue in China, downward pricing pressure to secure National Reimbursement Drug List (NRDL) inclusion remains the top challenge for multinational pharma companies in this market. However, the significant uptake post-NRDL inclusion and broad access offer substantial opportunities for innovative products with clinical differentiation.  In this white […]

Webinars

Dragon’s Offer: Imparting Wisdom About Market Access Through the NRDL in China

What do pharmaceutical manufacturers need to know to successfully navigate the market access landscape in China through the latest NRDL update? The access landscape in China is rapidly evolving with important implications for novel medicines. The most recent update of China’s National Reimbursement Drug List (NRDL) in 2021 focused on…

Watch Now

View All APAC Thought Leadership